Uploaded November 2026 | Updated November 2026, 7 hours ago
Sepsis is a systemic inflammatory response to infection, while severe sepsis is characterised by organ dysfunction due to dysregulated immune response. Septic shock is the most severe form of sepsis and results in reduced organ perfusion. Severe sepsis is associated with 30% mortality rate while that in septic shock is 30-40%. Globally, there are ~50 million cases of sepsis per year leading to 11 million deaths, making it a significant public health burden. Early diagnosis and prompt treatment are the critical in the management of severe sepsis and septic shock. However, sepsis-specific predictive biomarkers and organ protective therapeutics remain elusive.
In this study, we comprehensively profiled human serum from 31 patients suffering with varying degrees of septic shock stratified by vasoactive-inotropic score and 10 healthy donors using the OlinkExplore HT panel marking its first application in Australia. This proximity ligation approach allowed for simultaneous quantification of ~5,300 proteins in human serum, overcoming the inherent sensitivity issues with conventional mass spectrometry-enabled serum proteomics.
Our analysis revealed a distinct proteomic signature differentiating sepsis from healthy serum, highlighting circulating organ stress markers consistent with multi-organ failure, including cardiac, brain, lung, kidney, and muscle atrophy markers. Using our human cardiac organoid model, we then demonstrated cardiac dysfunction is directly induced by the sepsis serum, and can be attenuated by a novel epigenetic drug. In this pilot study, we were able to make direct correlations between serum proteins and the organoid functional outcome to uncover precise drivers of sepsis-induced cardiac dysfunction. Next, to uncover predictive biomarkers for organ-specific and pan-organ failure we performed a more advanced machine learning predictive analysis to identify secreted factors, such as cytokines, growth factors and metalloproteases associated with organ damage. Ongoing studies will assess the direct effect of these putative drivers on the relevant organs using human organoid models to identify potential therapeutic interventions.
Speaker: Harley Robinson, PhD - Research Officer, Cardiac Drug Discovery lab, QIMR Berghofer, Herston, QLD, Australia
Sepsis is a systemic inflammatory response to infection, while severe sepsis is characterised by organ dysfunction due to dysregulated immune response. Septic shock is the most severe form of sepsis and results in reduced organ perfusion. Severe sepsis is associated with 30% mortality rate while that in septic shock is 30-40%. Globally, there are ~50 million cases of sepsis per year leading to 11 million deaths, making it a significant public health burden. Early diagnosis and prompt treatment are the critical in the management of severe sepsis and septic shock. However, sepsis-specific predictive biomarkers and organ protective therapeutics remain elusive.
In this study, we comprehensively profiled human serum from 31 patients suffering with varying degrees of septic shock stratified by vasoactive-inotropic score and 10 healthy donors using the OlinkExplore HT panel marking its first application in Australia. This proximity ligation approach allowed for simultaneous quantification of ~5,300 proteins in human serum, overcoming the inherent sensitivity issues with conventional mass spectrometry-enabled serum proteomics.
Our analysis revealed a distinct proteomic signature differentiating sepsis from healthy serum, highlighting circulating organ stress markers consistent with multi-organ failure, including cardiac, brain, lung, kidney, and muscle atrophy markers. Using our human cardiac organoid model, we then demonstrated cardiac dysfunction is directly induced by the sepsis serum, and can be attenuated by a novel epigenetic drug. In this pilot study, we were able to make direct correlations between serum proteins and the organoid functional outcome to uncover precise drivers of sepsis-induced cardiac dysfunction. Next, to uncover predictive biomarkers for organ-specific and pan-organ failure we performed a more advanced machine learning predictive analysis to identify secreted factors, such as cytokines, growth factors and metalloproteases associated with organ damage. Ongoing studies will assess the direct effect of these putative drivers on the relevant organs using human organoid models to identify potential therapeutic interventions.
Speaker: Harley Robinson, PhD - Research Officer, Cardiac Drug Discovery lab, QIMR Berghofer, Herston, QLD, Australia










